Navigation Links
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Date:6/2/2008

lopment and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results of future trials will not correlate with the results of these trials and the risk that the results of future combination trials with other chemotherapeutic agents will not be consistent with the results of these trials. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly re
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
2. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
9. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
10. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
11. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 Patheon Inc ., a ... the global pharmaceutical industry, will host a complimentary webinar ... Testing” on Tuesday, June 4, 2013 at 11 a.m. ... required to comply with regulations for cleaning validation. ... scientific underpinning and little evaluation of risk. Some ...
(Date:5/23/2013)... 2013 VG Energy, an agricultural biotech ... Renewable Research to conduct field trials using LipidMax ... is a majority owned subsidiary of VG Life ... Energy,s exclusively licensed compound LipidMax selectively inhibits certain ... plants, possessing a wide variety of applications including ...
(Date:5/23/2013)... May 23, 2013 Z Trim Holdings, Inc. ... to a variety of industries, announced that Chef ... discussion at this year,s National Restaurant Association ("NRA") NRA ... behalf of the Research Chefs Association.  Chef Ryan spoke ... Good, the Bad and the Ugly," joining four other ...
(Date:5/23/2013)... 23, 2013 During the conduct ... to adhere to principles of good clinical practice ... speaker Dr. Jeremy Lim, Fellow, Clinical Development at ... ,     Understand the International Conference on Harmonization ... additional regulations for the conduction of clinical trials ...
Breaking Biology Technology:Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
... UW-Madison researchers may be moving toward ... disease, using stem cells. Also, students ... Technology Business Plan Contest, and Madison ... program. Original air date: Saturday, April ...
... biotech industry started in the late 1970s with the first IPOs ... an industry more than 25 years old. , ,An interesting article ... 1 states unequivocally that most industry cycles run about 50 years ... middle of its 50-year cycle. A new industry of significance usually ...
... Research institutions should create oversight committees to guide ... a panel of experts, including two University of ... , ,"In the absence of federal guidelines broadly ... embryonic stem cells, the scientific community and its ...
Cached Biology Technology:Biotech industry reaches midpoint in 50-year maturation cycle 2Biotech industry reaches midpoint in 50-year maturation cycle 3Biotech industry reaches midpoint in 50-year maturation cycle 4Biotech industry reaches midpoint in 50-year maturation cycle 5
(Date:5/22/2013)... conclude that the 20 percent reduction in lung ... chest X-ray (CXR) screening previously reported in the ... centers in the United States. , Philadelphia, PAPhysicians ... about the benefits and risks of LDCT lung ... New England Journal of Medicine of the ...
(Date:5/22/2013)... together in a major new effort to educate the ... Earth,s people with clean water that looms ahead in ... article in the current edition of Chemical & ... Chemical Society (ACS), the world,s largest scientific society. , ... Jerald L. Schnoor, Ph.D., explain that shortages of reliable ...
(Date:5/22/2013)... human health effects from disposal of millions of ... to recommend stronger government policies to encourage recovery, ... That,s the conclusion of a new paper in ... . , Oladele A. Ogunseitan and colleagues point ... powering everything from smart phones to components in ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... known as "dry water," which resembles powdered sugar, could ... dioxide, the major greenhouse gas that contributes to global ... the American Chemical Society. The powder shows bright promise ... may, for instance, be a greener, more energy-efficient way ...
... Lockheed Martin (NYSE: LMT ) and ZyGEM Corp. ... has potential to transform how law enforcement, homeland security and ... The prototype, called Rap I.D .™, will be ... session on Rapid DNA. The day-long session is sponsored by ...
... SEATTLE Super-sized electromagnetic coils are helping explain how ... being considered for placement along America,s coastal waters and ... of Energy,s Pacific Northwest National Laboratory are examining whether ... during and after exposure to an electromagnetic field similar ...
Cached Biology News:Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 2Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 3Magnetic attraction for fish, crabs? 2Magnetic attraction for fish, crabs? 3
... C-terminal end of the mouse retinoic acid receptor beta (RAR*). The ... RAR*. The sequence of PEP-005 is (amino to carboxy terminus): C ... - S - V - E - N - S - G ... - L - Q (The N-terminal cysteine has been added to ...
... potential applications for the use of small ... expression via the RNA interference (RNAi) pathway ... and molecular biology fields. siRNA for experimental ... chemically or enzymatically, and then transfected into ...
... automated hybridization system for the processing of ... hybridization and post hybridization washing of microarrays ... can process up to 12 slides at ... software, enabling the user to run all ...
... biological data hidden in your samples with eArray ... you to create your own microarray designs that ... own pace and receive delivery of your arrays ... a secure, online array creation application tool that ...
Biology Products: